News

The lung therapy developer Pulmatrix has obtained global rights to RespiVert’s respiratory-disease treatments under a licensing arrangement. Under the deal, Pulmatrix gained access to the kinase inhibitors that RespiVert has developed for lung conditions such as chronic obstructive pulmonary disease (COPD). Pumatrix also develops kinase inhibitors. RespiVert is a subsidiary of Janssen…

Blue Cross and Blue Shield of Texas (BCBSTX) is investing $10 million to raise awareness for the prevention and early detection of two diseases greatly affecting the health of Texans — chronic obstructive pulmonary disease (COPD) and chronic diabetic kidney disease (CKD) — through its Healthy Kids, Healthy Families grants…

Verona Pharma, a biopharmaceutical company developing therapeutics for the treatment of respiratory diseases, recently announced the initiation of a clinical trial in the United States for its product RPL554. The drug is currently in development for patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Announcement of the clinical trial follows the…

Sunovion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA), clearing the Massachusetts company from having to conduct further clinical trials for approval of its SUN-101/eFlow (glycopyrrolate) therapy to treat chronic obstructive pulmonary disease (COPD). According to a corporate press release, the CRL clears Sunovion…

Dutch healthcare conglomerate Royal Philips has purchased RespirTech, a leading manufacturer of airway clearance therapy vests for patients with chronic obstructive pulmonary disease (COPD) and other severe lung conditions. With this new acquisition, Philips expands its respiratory care portfolio, strengthening its presence in the hospital and home care markets —  especially…

A recent study, co-sponsored by Royal Philips, showed that using home noninvasive ventilation in addition to home oxygen therapy (HOT) could effectively delay hospital readmissions and increase survival in patients with advanced chronic obstructive pulmonary disease (COPD) after a life-threatening respiratory event or exacerbation. The study, “Effect of Home Noninvasive…

Using a ventilator to control the level of supplemental oxygen a chronic obstructive pulmonary disease (COPD) patient receives halved patients’ trips to the hospital from disease flare-ups, according to a clinical trial. Britishers researchers conducted the study, which they dubbed the Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) trial (…

Ndd Medical Technologies will showcase the latest versions of its best-in-class spirometer and portable, all-in-one DLCO (diffusing capacity for carbon monoxide) devices for lung conditions such as chronic obstructive pulmonary disease (COPD) and asthma at an upcoming conference in the nation’s capital. The annual American Thoracic Society (ATS 2017) Conference is…

Sunovion Pharmaceuticals will present data from Phase 3 studies of SUN-101/eFlow as a potential maintenance therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society 2017 International Conference (ATS 2017), to be held May 19-24 in Washington, D.C. Sunovion will also present data on both Brovana…

Pulmatrix has received a key U.S. patent for its lead inhaled drug candidate PUR0200 to treat chronic obstructive pulmonary disease (COPD). The drug, still under development in the United States and Europe, is a long-acting muscarinic antagonist (LAMA) bronchodilator. Thanks to Pulmatrix’s iSPERSE technology, PUR0200 can reportedly achieve the same effect…